Shree Ganesh Bio

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE051N01026
NSEID:
BSEID: 539470
View on BSE

INR

0.66

0.01 (1.54%)

BSENSE

Feb 04

BSE+NSE Vol: 8.18 lacs

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Colinz Labs

Desh Rakshak

Guj. Terce Labs.

Ishita Drugs

Shree Ganesh Bio

Zenith Health

ANG Lifesciences

Medi Caps

Chandra Bhagat

Venmax Drugs

Medicamen Organ.

Why is Shree Ganesh Biotech India Ltd ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.82
The company has been able to generate a Return on Equity (avg) of 2.62% signifying low profitability per unit of shareholders funds

Flat results in Dec 25

DEBTORS TURNOVER RATIO(HY) Lowest at 0.00 times

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -32.65%, its profits have fallen by -115.5%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shree Ganesh Bio for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Shree Ganesh Bio

-32.65%

-1.01

32.19%

Sensex

6.66%

0.57

11.66%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-6.20%

EBIT Growth (5y)

-203.19%

EBIT to Interest (avg)

0.82

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.12

Sales to Capital Employed (avg)

0.64

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

1.42%

ROCE (avg)

1.52%

ROE (avg)

2.62%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.41

EV to EBIT

-9.55

EV to EBITDA

-9.55

EV to Capital Employed

0.33

EV to Sales

3.16

PEG Ratio

Dividend Yield

ROCE (Latest)

-2.54%

ROE (Latest)

-0.46%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

PAT(9M)

Higher at Rs 0.66 Cr

-1What is not working for the Company

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.00 times

Loading Valuation Snapshot...

Here's what is working for Shree Ganesh Bio

Profit After Tax (PAT) - Nine Monthly

Higher at Rs 0.66 Cr

than preceding 12 month period ended Dec 2025 of Rs 0.38 cr

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

PAT (Rs Cr)

Here's what is not working for Shree Ganesh Bio

Debtors Turnover Ratio- Half Yearly

Lowest at 0.00 times

in the last five half yearly periods

MOJO Watch

Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio